Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, a new study found.

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

Car-T cell therapy has changed the face of many cancer treatments, but the level of customization it requires still comes ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

ROCHESTER, Minn. — Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This ...

CAR-T Therapy Won't Raise Odds for a Second Cancer, Study Finds By Ernie Mundell HealthDay Reporter WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- Contrary to a warning placed on labels for CART-T ...

Overall, 5.8% of patients developed the new cancers. Four of the trials compared outcomes for patients who received CAR-T therapy versus standard regimens. Rates of secondary cancers were similar ...

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clinical Cancer Research , 2024; DOI: 10.1158/1078-0432.CCR-24-1798 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of ...

A new study finds that one form -- CAR-T therapy -- can be successfully and safely delivered in an outpatient setting ...

T-cell exhaustion causes relapse in many patients within a year of receiving CAR-T cell therapy. In search of new solutions, Dr. Kenderian's team analyzed pre-infusion CAR-T cells from patients ...

TUESDAY, Oct. 1, 2024 (HealthDay News) -- Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, the largest study examining its use in a community ...